arrow
J

Julien Kirchgesner

assistance publique - hôpitaux de paris
H指数:34
被引数:5,149

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Acceptability of probiotics, fecal microbiota transplantation, and emerging microbiome-derived therapies in patients with inflammatory bowel diseases: A cross-sectional Survey Study

炎症性肠病患者对益生菌、粪菌移植及新兴肠道菌群衍生疗法的接受度:一项横断面调查研究

2026-10-010
PRE
Methotrexate for inflammatory bowel disease: the MICI-METHO multicenter retrospective cohort study

甲氨蝶呤治疗炎症性肠病:MICI-METHO多中心回顾性队列研究

2026-07-220
PRE
Five-year effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor

239例对肿瘤坏死因子拮抗剂无应答的克罗恩病患者中,ustekinumab或vedolizumab的五年疗效。

2025-12-050
PRE
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID

皮下注射维多利珠单抗剂量强化在炎症性肠病患者中的应用:GETAID组织的OPTI-VEDO多中心研究

2025-09-010
PRE
Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey

欧洲克罗恩结肠炎组织护理质量标准与欧洲IBD单位结构的现实世界之间的差距: 电子质量调查的结果

2025-07-012
PRE
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey

Fiorino, G.; Fidalgo, C.; Adamina, M.; Barreiro-de Acosta, M.; Ali, M.P.; Bortlik, M.; Burisch, J.; Dignass, A.; Drobne, D.; Faiz, O.; 等. 欧洲克罗恩病与溃疡性结肠炎组织护理质量标准与实际诊疗在诊断和监测炎症性肠病方面的差距:欧洲E-QUALITY调查结果. J. Crohn’s Colitis 2025, 19, jjaf105. [Google Scholar] [CrossRef] [PubMed]

2025-07-011
PRE
Faecalibacterium Diversity in the Gut Microbiome of Crohn's Disease Patients

克罗恩病患者肠道微生物组中的Faecalibacterium多样性

2025-04-190
OAAI
Efficacy and safety of a second JAK inhibitor in Ulcerative Colitis: J2J multicenter cohort
2025-01-220
PRE
Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO study
2025-01-220
PRE